P57 Predicting late responders to filgotinib in patients with ulcerative colitis: a post hoc analysi...
P57 Predicting late responders to filgotinib in patients with ulcerative colitis: a post hoc analysis of SELECTION and SELECTIONLTE
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
IntroductionFilgotinib (FIL) is an oral, JAK1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). In the SELECTION programme patients’ C-reactive protein, rectal bleeding and stool frequency at day 7 predicted response to FIL at week 10. Patients who did not respond to induction (IND) FIL benefited from an additional 12 we...
Alternative Titles
Full title
P57 Predicting late responders to filgotinib in patients with ulcerative colitis: a post hoc analysis of SELECTION and SELECTIONLTE
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_04264892v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04264892v1
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2023-BSG.129
